Matrixyl¶
Identification¶
| Property | Value |
|---|---|
| CAS Number | 214047-00-4 |
| Molecular Formula | C₃₉H₇₅N₇O₁₀ |
| Molecular Weight | ~803.9 Da |
| Sequence | Palmitoyl-Lys-Thr-Thr-Lys-Ser-OH |
| Amino Acid Count | 5 (N-terminal palmitoyl) |
| Appearance | White to off-white lyophilized powder |
| Purity Standard | ≥99% by HPLC |
| Solubility | Lipid-soluble; limited aqueous solubility |
| Storage | 2–8°C, desiccated, protect from light |
Category: Cosmetic & Skin
Catalog SKU: PSH-MATRX-10MG
Research Background¶
Matrixyl (Palmitoyl Pentapeptide-4) is a lipopeptide designed around the concept of 'matrikine' signaling — using small peptide fragments of extracellular matrix proteins to stimulate the skin's own repair mechanisms. It consists of the pentapeptide Lys-Thr-Thr-Lys-Ser conjugated to a palmitic acid (C16) chain for enhanced skin penetration. Unlike neurotransmitter-targeting peptides (Argireline, Snap-8), Matrixyl addresses expression lines from the structural side — rebuilding dermal matrix components rather than inhibiting muscle contraction.
Key Mechanisms¶
| Mechanism | Details |
|---|---|
| Matrikine Signaling | Collagen fragment mimetic → activates fibroblast ECM synthesis programs |
| TGF-β Pathway | Stimulates TGF-β → procollagen I/III transcription in dermal fibroblasts |
| Palmitoyl Anchoring | C16 palmitoyl chain → enhanced stratum corneum partitioning and dermal delivery |
Research Focus Areas¶
Collagen Synthesis¶
Procollagen I and III upregulation in dermal fibroblast models
ECM Remodeling¶
Fibronectin and elastin production stimulation
Wrinkle Reduction¶
Dermal matrix regeneration in photoaged skin models
Skin Firmness¶
Increased dermal density and elasticity in clinical research
Available Configurations¶
| Configuration | Content | Best For |
|---|---|---|
| Standard Kit | 10 mg × 10 vials | ECM research; formulation evaluation |
| Bulk Kit | 50 mg × 10 vials | Product development; pilot batches |
| Custom | Custom mg × custom vials | OEM; private-label cosmetics |
Tiered Wholesale Pricing¶
| Volume | Discount | For |
|---|---|---|
| 1 kit | List price | Evaluation; competitive analysis |
| 5+ kits | 10% off | Initial portfolio expansion |
| 20+ kits | 20% off | Mid-size distributors |
| 50+ kits | 30% off | Regional distributors |
Quality Specifications¶
| Parameter | Method | Criterion |
|---|---|---|
| Purity | HPLC at 214 nm, C18 column | ≥99.0% peak area |
| Identity (MW) | ESI-MS | ~803.9 ± 1.0 Da |
| Appearance | Visual inspection | White to off-white powder |
| Peptide Content | Amino acid analysis | ≥80% net peptide |
| Residual Moisture | Karl Fischer | ≤3% |
Frequently Asked Questions¶
Q1: How does Matrixyl differ from other cosmetic peptides?¶
Matrixyl targets the structural extracellular matrix (collagen, elastin, fibronectin synthesis) rather than neuromuscular signaling. While Argireline/Snap-8 reduce lines by inhibiting contraction, Matrixyl rebuilds dermal matrix components through matrikine signaling.
Q2: What is the purpose of the palmitoyl group?¶
N-terminal palmitoyl (C16) dramatically enhances stratum corneum penetration by partitioning into the lipid-rich intercellular matrix, and anchors the peptide at the cell membrane, prolonging fibroblast receptor interaction. Without it, dermal delivery would be negligible.
Q3: What does 'matrikine' mean?¶
Matrikines are peptide fragments released during ECM degradation that signal cells to initiate repair. Matrixyl mimics this by presenting a collagen-derived peptide sequence to fibroblasts — 'tricking' cells into believing ECM damage has occurred, triggering repair.
Q4: Is Matrixyl compatible with other cosmetic peptides?¶
Yes. Matrixyl's ECM-building mechanism is complementary to neurotransmitter-targeting peptides (Argireline, Snap-8) and copper peptides (GHK-Cu). Multi-peptide formulations combining matrikine + neurotransmitter inhibitor + carrier peptide are common research strategies.
Q5: What purity is Matrixyl supplied at?¶
≥99% by HPLC at 214 nm. Palmitoylation efficiency (>98%) verified by HPLC with ELSD detection. Batch-specific COA included.
Key Research References¶
| Reference | PMID | Key Finding |
|---|---|---|
| Lintner K & Peschard O. "Biologically active peptides: from a laboratory bench curiosity to a functional skin care product." Int J Cosmet Sci. 2000;22(3):207–218. | 18503476 | Matrixyl (palmitoyl pentapeptide-4) design concept: matrikine signaling via collagen fragment mimetic; palmitoyl anchor for stratum corneum penetration |
| Robinson LR et al. "Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin." Int J Cosmet Sci. 2005;27(3):155–160. | 18492182 | Clinical study: topical Matrixyl reduced wrinkle depth and improved skin firmness through procollagen I/III upregulation in photoaged skin |
Stability & Storage¶
| Condition | Degradation Profile |
|---|---|
| Lyophilized Storage | Standard peptide stability; 24 months at 2–8°C in desiccated environment, protect from light |
| Palmitoyl Stability | N-terminal palmitoyl (C16) enhances structural stability and skin penetration; monitor for hydrolysis of palmitoyl-peptide bond |
| Neutral pH (5.0–7.0) | Stable; recommended for reconstitution and formulation. Palmitoyl group imparts limited aqueous solubility — use co-solvents in formulation |
| Reconstituted Solution | 24 h at 2–8°C; aliquot and freeze at −20°C for extended use. Expect limited aqueous solubility due to lipophilic C16 chain |
Source & Purchase¶
For research-grade MATRIXYL and related compounds in this category, visit the PeptideSourceHub category page for bulk pricing and available specifications.
Browse MATRIXYL & Related Products →
Related Products¶
| Product | Link |
|---|---|
| GHK-Cu (Copper Tripeptide) | ghk-cu.md — Copper peptide for collagen synthesis & wound healing |
| Argireline (Acetyl Hexapeptide-8) | argireline.md — SNARE complex inhibitor |
| Leuphasyl (Pentapeptide-18) | leuphasyl.md — δ-opioid receptor agonist |
| Snap-8 (Acetyl Octapeptide-3) | snap-8.md — SNAP-25 competition peptide |